99726 20230519145504.0 doi 10.3390/pharmaceutics13020217 sideral 123225 ART-2021-123225 eng Rodrigo, M.J. Monitoring new long-lasting intravitreal formulation for glaucoma with vitreous images using optical coherence tomography 2021 Access copy available to the general public Unrestricted Intravitreal injection is the gold standard therapeutic option for posterior segment patholo-gies, and long-lasting release is necessary to avoid reinjections. There is no effective intravitreal treatment for glaucoma or other optic neuropathies in daily practice, nor is there a non-invasive method to monitor drug levels in the vitreous. Here we show that a glaucoma treatment combining a hypotensive and neuroprotective intravitreal formulation (IF) of brimonidine–Laponite (BRI/LAP) can be monitored non-invasively using vitreoretinal interface imaging captured with optical coherence tomography (OCT) over 24 weeks of follow-up. Qualitative and quantitative characterisation was achieved by analysing the changes in vitreous (VIT) signal intensity, expressed as a ratio of retinal pigment epithelium (RPE) intensity. Vitreous hyperreflective aggregates mixed in the vitreous and tended to settle on the retinal surface. Relative intensity and aggregate size progressively decreased over 24 weeks in treated rat eyes as the BRI/LAP IF degraded. VIT/RPE relative intensity and total aggregate area correlated with brimonidine levels measured in the eye. The OCT-derived VIT/RPE relative intensity may be a useful and objective marker for non-invasive monitoring of BRI/LAP IF. info:eu-repo/grantAgreement/ES/ISCIII/M17-00213 info:eu-repo/grantAgreement/ES/ISCIII/PI17-01726 info:eu-repo/grantAgreement/ES/ISCIII/PI17-01946 info:eu-repo/grantAgreement/ES/MINECO-AEI-FEDER/MAT2017-83858-C2-2 info:eu-repo/semantics/openAccess by http://creativecommons.org/licenses/by/3.0/es/ 6.525 2021 PHARMACOLOGY & PHARMACY 39 / 279 = 0.14 2021 Q1 T1 0.922 2021 Pharmaceutical Science 2021 Q1 6.0 2021 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Pérez Del Palomar, A. Universidad de Zaragoza (orcid)0000-0003-0669-777X Montolío, A. Universidad de Zaragoza (orcid)0000-0001-7248-4399 Mendez-Martinez, S. Universidad de Zaragoza (orcid)0000-0001-6072-1545 Subias, M. Cardiel, M.J. Universidad de Zaragoza (orcid)0000-0002-7914-4685 Martinez-Rincon, T. Cegoñino, J. Universidad de Zaragoza (orcid)0000-0002-2967-6747 Fraile, J.M. (orcid)0000-0002-0136-5138 Vispe, E. (orcid)0000-0002-4921-4734 Mayoral, J.A. Universidad de Zaragoza (orcid)0000-0003-1570-4257 Polo, V. Universidad de Zaragoza (orcid)0000-0002-1402-3129 Garcia-Martin, E. Universidad de Zaragoza (orcid)0000-0001-6258-2489 2013 765 Universidad de Zaragoza Dpto. Química Orgánica Área Química Orgánica 1013 646 Universidad de Zaragoza Dpto. Cirugía Área Oftalmología 5004 605 Universidad de Zaragoza Dpto. Ingeniería Mecánica Área Mec.Med.Cont. y Teor.Est. 1013 020 Universidad de Zaragoza Dpto. Cirugía Área Anatomía Patológica 13, 2 (2021), 217 [16 pp] Pharmaceutics Pharmaceutics 1999-4923 898427 http://zaguan.unizar.es/record/99726/files/texto_completo.pdf Versión publicada 2706904 http://zaguan.unizar.es/record/99726/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:99726 articulos driver 2023-05-18-15:03:33 ARTICLE